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Abstract
Background: Chronic hemodialysis patients are at higher risk for acquiring hepatitis C virus
(HCV). The prevalence varies among different countries and hemodialysis centers. Although
guidelines for a comprehensive infection control program exist, the nosocomial transmission still
accounts for the new cases of infection. The aim of this study was analyze the follow up of newly
acquired acute hepatitis C cases, during the period from January 2002 to May 2005, in the
Hemodialysis Center, located in the Southwest region of Parana State, Brazil and to analyze the
effectiveness of the measures to restrain the appearance of new cases of acute hepatitis C.
Methods: Patients were analyzed monthly with anti-HCV tests and ALT measurements. Patients
with ALT elevations were monitored for possible acute hepatitis C.
Results: During this period, 32 new cases were identified with acute hepatitis C virus infection.
Blood screening showed variable ALT levels preceding the anti-HCV seroconversion. HCV RNA
viremia by PCR analysis was intermittently and even negative in some cases. Ten out of 32 patients
received 1 mcg/kg dose of pegylated interferon alfa-2b treatment for 24 weeks. All dialysis
personnel were re-trained to strictly follow the regulations and recommendations regarding
infection control, proper methods to clean and disinfect equipment were reviewed and HCV-
positive patients were isolated.
Conclusion: Laboratory tests results showed variable ALT preceding anti-HCV seroconversion
and intermittent viremia. The applied recommendations contributed importantly to restrain the
appearance of new cases of acute hepatitis C in this center and the last case was diagnosed in May
2004.
Background
Hepatitis C virus (HCV) prevalence differs among hemo-
dialysis units according to their geographical location,
health care procedures, socioeconomic factors, reuse of
lines, hygiene and sterilization of equipment, patient
rotation of machines and the undertaking of rigorous uni-
versal precaution rules. These features influence the risk of
nosocomial transmission of HCV to hemodialysis
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patients [1-3]. Previous reports reinforces the importance
of vigilance in these units [2,4,5], especially the strict fol-
lowing of recommendations to prevent the transmission
of infectious diseases among these patients [6].
In chronic renal patients, hepatitis C virus infection is
often difficult to evaluate. The results of assays used to
diagnose this infection can be hard to interpret due to the
particular features found in this population. The identifi-
cation of acute HCV infection cases can be influenced by
several factors: a) absence of symptoms in acute cases, the
majority of them without jaundice and with symptoms
related to the base of the disease or to chronic anemia; b)
slight increases of aminotransferases levels; C) anti-HCV
negative serology or positive after several months of con-
tamination; and d) intermittent viremia. Patients present-
ing intermittent viremia were described in 33% to 67% of
anti-HCV positive patients [7-9]. The levels of alanins
aminotransferase (ALT) are generally lower in patients
with renal failure. Previous reports shown the need to
establish lower ALT levels standard to increase the accu-
racy of this assay in detecting liver diseases [10-12].
The aims of this study were to follow the development of
acute hepatitis C cases in a renal therapy unit located in
the southeast of Parana from January 2002 to May 2005,
and the response to the measures taken to avoid new acute
hepatitis C cases.
Methods
Study design
From January 2002 to May 2005, we prospectively fol-
lowed up all patients at a single hemodialysis unit in Pato
Branco city, southeast Parana, Brazil. The study patients
were prospectively tested every month by a third-genera-
tion anti-HCV ELISA. Positive results obtained by ELISA
test were confirmed by HCV RNA testing. ALT determina-
tion in the study group was performed each month.
Determination of HCV RNA and HCV genotype
Serum HCV RNA was detected as follows: RNA was
extracted from 100 micro liters of serum by guanidinium
isothiocyanate, phenol chloroform extraction described
by Chomczynski & Sacchi [13]. Complementary DNA was
synthesized using random primers and reverse tran-
scriptase Moloney Murine Leukemia Virus (M-MLV) (Inv-
itrogen Life Technologies, Carlsbad, CA, USA). HCV RNA
was detected by two-stage polymerase chain reaction
(PCR) using primers from the 5' – untranslated region of
the HCV genome, as previously described [14]. HCV gen-
otypes of the patients with HCV viremia were determined
by sequencing (Applied Biosystems, Foster city, CA, USA),
as previously described [14].
IFN therapy and follow-up
Infected patients were informed of the possible risks and
benefits of IFN treatment. Ten out 32 patients diagnosed
with acute hepatitis C were treated with pegylated inter-
feron 1 mcg/kg/weekly for 24 weeks. Pegylated IFN-a 2b
(Intron A; Schering-Plough Corp., Kenilworth, NJ) was
patient-administered subcutaneously at doses of 1 micro-
gram/kg/weekly for 24 weeks. Each patient check-up
included measurement of serum ALT levels and a com-
plete blood count, and this was done in the outpatient
clinic at 1-week intervals during the first month, at 2-week
intervals during the second and third months of treat-
ment, and monthly after the end of the treatment. Serum
HCV RNA was assessed qualitatively before treatment, at
end of treatment and at month 6 post-treatment. Sus-
tained virological response was considered in cases with
undetectable HCV RNA 6 months after the end of treat-
ment.
All patients gave written informed consent. The study was
approved by the local hospital ethical committee and
Clinical Hospital of the University of São Paulo School of
Medicine.
Infection control training and education
After the detection of new acute hepatitis C cases, more
stringent precautions were taken at the hemodialysis units
to reduce the appearance of new cases.
The measures were based on different publications and
recommendations [3,6,15-17] and in brief are summa-
rized as follows:
a) Reeducation of existing staff members regarding Rec-
ommended Infection Control Practices for Hemodialysis.
b) All the equipment used on patients with positive serol-
ogy, such as stethoscope, sphygmomanometer, and
Micropore dressings were separated. Isolated carts were
installed for use according to anti-HCV serology.
c) Patients attending the unit who had been transferred
from another centre and with ALT alterations were iso-
lated until serological confirmation.
d) As in 2002 new cases continued to arise, it was decided
to separate patients with anti-HCV positive to undergo
dialysis sessions on Mondays, Wednesdays and Fridays,
while the anti-HCV negative patients to Tuesdays, Thurs-
days and Saturdays, always utilizing the same machine for
each patient. The transportation of patients was separated
in accordance to HCV serology or HCV-RNA because of
the possibility of episodes of vascular bleeding (fistula)
due to heparinization.BMC Public Health 2007, 7:50 http://www.biomedcentral.com/1471-2458/7/50
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e) Hemodialysis machines were sterilized after each ses-
sion of dialysis with Persteril 3.5 [peracetic acid 3.5%] and
externally cleaned with soap and water. There were also
changes in the sterilizing procedures of the lines (reuse).
The lines were sterilized in separate rooms, conforming to
serology (anti-HCV positive, anti-HCV negative HBsAg
positive), in semi-automatic reprocessing device for up to
10 lines, to sterilizing the lines of patients with anti-HCV
negative serology in individual automatic reprocessing
device (Renatron, Minntech Renal Systems) with hydro-
gen peroxide 20%, peracetic acid 4.5%. The lines were
reused in accordance with the internal number of them
(priming), being discarded with priming < 80% or
depending on its reuse, no more than 12 times when
reprocessed manually, or up to 20 times when reproc-
essed automatically, in agreement with the resolution –
RDC # 154, 15th of July 2004 [18].
f) The health-care workers from the unit were examined
for anti-HCV (12 nursing technicians, 2 nurses, 2 nephrol-
ogy doctors and 2 maintenance workers) and were all
serologically negative.
Results
Table 1 shows the number of patients followed at the
hemodialysis unit. We identified by anti-HCV ELISA 32
patients with acute HCV infection over the study period.
A higher number of cases at the initial stages of the studies
were diagnosed and their number decreased over the sub-
sequent years (Table 2).
Ten patients were selected for treatment. We used
pegylated interferon alfa 2b, at dose of 1 mcg/Kg body
weight, during 24 weeks. The selected patients could not
be standardized in relation to the onset of the disease.
Patients started treatment an average 6.9 ± 3.5 months
after the first HCV was positive. Of the 10 patients treated,
four (cases 14, 16, 23, 32) had sustained virological
response, three (cases 15, 19, 24) did not responded to
treatment, one patient (case 31) died during treatment,
owing to fistula infection and pneumonia, without evi-
dence of leukopenia. One patient (case 27) with a high
ALT level and anti-HCV seroconversion received treat-
ment and was HCV-RNA negative in the samples collected
thereafter. Another patient (case 25), from whom samples
of HCV-RNA were taken 3 months prior to treatment, did
not showed a positive PCR, therefore we could not deter-
mine if these two cases responses were due to natural
causes or therapeutic response.
At the end of the investigation, among the 32 cases with
acute HCV infection, 12 patients had detectable PCR-RNA
(one case treated), 10 had PCR-RNA not detected (six
treated), nine deaths (three treated) and the loss of one
case report (hemodialysis unit changed)
HCVgenotyping showed 22 cases infected with type 1
three cases with type 3 (Table 3). In seven cases, it was not
possible to carry out the genotyping because of negative
HCV RNA at the samples.
Liver biopsy was carried out on just three patients, with-
out adverse events, all presenting slight histological alter-
ations according to the Brazilian Society of Pathology
classification. A histological study was not carried out on
the other patients. After the detection of new acute hepa-
titis C virus cases and their treatment, measures were
taken to restrain other detected outbreaks and reduce the
appearance of new cases.
The measures established were based on different publica-
tions and recommendations by the National Agency of
Sanitary Vigilance [18,3,6,15-17] and followed as
described above in the Material and Methods section.
As in 2002 new cases continued to arise, it was decided to
separate patients with anti-HCV positive to undergo dial-
ysis sessions on Mondays, Wednesdays and Fridays, while
the anti-HCV negative patients to Tuesdays, Thursdays
and Saturdays, always utilizing the same machine for each
patient.
With the measures established the hepatitis C outbreak
was controlled and last case of acute hepatitis C seen in
this unit was May 2004.
Discussion
Nosocomial transmission of the HCV in dialysis units is
not a rare event observed world wide. However, the detec-
tion of acute HCV infection continues to be a challenge
among this population.
The present study of haemodialysis patients lasted for 41
months and showed a high incidence of new hepatitis C
cases over a short period, characterizing an outbreak of
HCV infection in this unit.
Table 1: Number of patients followed at the hemodialysis center 
and acute hepatitis C new cases
2002 2003 2004 May/2005
Initial total number of patients 74 86 87 71
Admissions 40 32 37 21
Deaths 12 15 18 04
Drop-outs 13 09 16 09
Kidney transplantations 03 07 19 03
Total number of patients 86 87 71 76
Total acute hepatits C new cases 20 06 06 00BMC Public Health 2007, 7:50 http://www.biomedcentral.com/1471-2458/7/50
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During the investigation (January 2002 to May 2005), 32
new cases of acute hepatitis C were diagnosed. The detec-
tion of acute HCV infection was carried out through
monthly ALT and anti-HCV markers observation. ALT ele-
vations at the initial stages of HCV infection varied among
patients, reaching a maximum of 325 IU/L, preceding up
to 4 months the appearance of anti-HCV in the serum. It
should be noted that the antibody in hemodialysis
patients makes slower appearance than in non-hemodial-
ysis patients and seroconversion may depend on each
patient response. Therefore HCV RNA screening would be
advisable, but a cost-effective analysis should be consid-
ered in this situation. To rule out false-positive ELISA in
patients tested negative for HCV RNA, the immunoblot
assay is still useful as a supplemental assay [19]. However,
this is sometimes not available everywhere due to costs of
the method.
The baseline levels of ALT in patients on dialysis are much
lower than that of the general population. The study by
Guh et al [10], suggests that the cutoff for the detection of
HCV infection should be 16 UI/I for ALT and 18UI/I for
aspartate transaminase (AST). Gouveia et al [20], suggest
that higher normal limits of ALT should be reduced to
60% of conventional limits, when evaluating renal failure
patients on dialysis. These lower levels are not yet fully
accepted. Our results confirm the importance of monthly
surveillance of ALT and that in even mild increases of the
monthly standard can indicate acute HCV infection.
The confirmation of acute HCV infection is made by the
detection of viremia. In our study confirmation was made
by the detection of HCV-RNA using the Polymerase Chain
Reaction (PCR). PCR is a good diagnostic test of HCV
infection in chronic renal patients, despite observing var-
Table 3: HCV genotype from the 32 cases of acute HCV
Genotype Total
12 2
33
Not done 7
Total 32
Table 2: ALT levels 4 months before anti-HCV seroconversion from patients followed up from January 2002 to May 2005
Case number ALT levels 4 months before seroconversion ALT/Anti-HCV seroconversion month
01 17 12 28 223 20/March 2002
02 10 28 325 253 179/March 2002
03 27 162 248 13 19/April 2002
04 16 21 76 250 15/May 2002
05 26 34 26 63 280/May 2002
06 12 11 57 179 56/May 2002
07 14 13 17 22 19/May 2002
08 24 19 34 33 63/May 2002
09 22 52 73 164 178/May 2002
10 18 35 85 270 26/May 2002
11 03 25 18 78 179/July 2002
12 25 14 143 111 203/July 2002
13 04 05 15 250 318/July 2002
14 15 26 13 226 31/August 2002
15 11 04 25 253 187/August 2002
16 61 69 201 61 190/September 2002
17 07 22 29 246 159/September 2002
18 16 29 84 102 73/September 2002
19 66 17 18 45 124/September 2002
20 25 37 30 105 275/November 2002
21 26 39 183 100 304/January 2003
22 05 07 38 174 110/January 2003
23 04 14 50 111 18/January 2003
24 37 40 39 28 114/January 2003
25 14 69 318 158 99/November 2003
26 11 38 31 85 52/November 2003
27 08 24 186 36 08/January 2004
28 12 51 114 195 223/January 2004
29 14 08 12 94 -/February 2004
30 26 28 41 33 203/March 2004
31 - - 14 24 103/April 2004
32 07 11 63 54 54/May 2004BMC Public Health 2007, 7:50 http://www.biomedcentral.com/1471-2458/7/50
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iations in up to two thirds of patients possibly related to
PCR inhibitors, that could be more frequent in patients on
dialysis [21]. If positive, it suggests the presence of infec-
tion and makes possible the evaluation of the genotype.
Another difficulty of this exam is that it is carried out in
specialized laboratories prepared for molecular biology
studies. Besides the technical characteristics of this
method, another problem related to the intermittent
viremia in these patients, is the need to carry out the
exams repeatedly, representing a technical limitation and
increasing costs.
Acute HCV infection cases, with confirmed viremia and
without viral clearance up after 12 weeks, should be care-
fully evaluated for treatment, thus reducing the risks of the
patients becoming chronic, which could worsen life
expectancy, as in the response to renal transplantation.
Many investigators recommend interferon treatment for
24 weeks [22,23]. Use of Ribavirin is not indicated in
these patients because of the risk of hemolytic anemia
[24,25]. Pegylated interferon alfa 2b is excreted by the kid-
neys, therefore we used a lower dose (1 mcg per Kg) [26].
In our study, the selected patients could not be standard-
ized in relation to the onset of the disease. Of the 10
treated patients, four had sustained virological response,
three did not responded to treatment, one died during
treatment, owing to fistula infection and pneumonia,
however without evidence of leukopenia. One patient
[27] with high ALT and seroconversion anti-HCV,
received treatment, and had all collected samples clear of
HCV-RNA. Another patient [25], whose samples of pre-
treatment HCV-RNA were collected 3 months prior to
treatment, developed non-detectable PCR, however, these
cases cannot confirmed if it was due to therapeutic
response or natural causes.
In the light of a HCV infection outbreak seen in our
haemodialysis unit, we adopted concomitant measures
for its identification, as well as the containment of new
cases appearing. These measures included the retraining
of personnel in relation to universal biosafety guidelines
and universal precautions [6] and the importance of the
health-care workers and controls in the nosocomial trans-
mission. The patients were isolated in turns with positive
serology for anti-HCV, this separation was also done
while patients were in transfer because of possible vascu-
lar bleeding due to heparinization during dialysis [27]. All
equipment utilized on patients was also separated. The
procedure for sterilizing the dialysis machines was
revised; the reprocessing device was modified using auto-
matic and individual reprocessing in cases of negative
serology.
In the haemodialysis units, the risk of infection has been
related to the patients and units, characterizing nosoco-
mial transmission [2,28].
Pinto dos Santos et al [3] suggest that HCV transmission
in haemodialysis units can be reduced by isolation of
HCV positive patients, using separate machines and iso-
lating the reused lines. As well as these investigators we
observed the reduction of new cases after the isolation of
cases in specific shifts. On the other hand, Jadoul et al [15]
reinforce that only the following of universal rules and
precautions would be enough to prevent transmission of
HCV in haemodialysis units, without the need to isolate
infected patients.
The effectiveness of isolation measures to prevent HCV
infections is controversial. The strict observance of univer-
sal precautions has been sufficient to prevent nosocomial
transmission of HCV. However, when selective isolation
measures, such as, separation of equipment and patients,
in a specific area of the unit, have been adopted, specially
in units of high prevalence of HCV and also when the
patient/health-care worker ratio is low, this involuntary
favors the breach of universal precautions [1,28]. Despite
some controversy, in our case, the measures established
were fundamental for the containment of the hepatitis C
outbreak, the last case being registered 12 months from
the end of the study.
Conclusion
It can be concluded that nosocomial transmission contin-
ues to have a major role in the transmission of HCV in
haemodialysis units, that acute HCV infection be moni-
tored and measures established to control the outbreak of
new cases, and those cases with persistent viremia after 12
months, should be included in treatment procedures.
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